Investment Summary |
|
|---|---|
| Date | 2021-03-01 |
| Target | Parabilis Medicines |
| Sector | Life Science |
| Investor(s) |
HBM Partners
Farallon Capital Management Invus Group GV Investments Deerfield Management |
| Deal Type | Venture |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 55 of 65 |
| Sector: Life Science M&A | 48 of 56 |
| Type: Venture M&A Deals | 43 of 52 |
| State: Massachusetts M&A | 8 of 13 |
| Country: United States M&A | 37 of 44 |
| Year: 2021 M&A | 8 of 15 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-22 |
Fore Biotherapeutics
Philadelphia, Pennsylvania, United States Fore Biotherapeutics is a biotechnology company developing compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Fore Biotherapeutics’ lead program, PLX-8394, is in clinical development for BRAF-mutated tumors without approved therapies. Fore Biotherapeutics was founded in 2011 and is based in Philadelphia, Pennsylvania. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-03-02 |
eGenesis
Cambridge, Massachusetts, United States eGenesis is a biotechnology company using breakthrough gene-editing technologies for the development of safe and effective human-compatible organs, tissues, and cells. eGenesis was founded in 2015 and is based in Cambridge, Massachusetts. |
Buy | - |
| Category | Asset Manager |
|---|---|
| Founded | 1986 |
| Size | Large |
| Type | Sector Agnostic |
Farallon Capital Management is a private investment firm that targets a variety of investment strategies throughout the world. The Firm pursues investments that include public and private debt and equity securities, direct investments in private companies, and real estate. Farallon is especially interested in investments that include a key event (such as a merger, restructuring, recapitalization or other major change) that has the potential for an appreciation of the value of a particular investment. Farallon's direct investment group makes debt, preferred stock or equity investments in businesses with substantial franchise value, healthy cash flow, and motivated management who have invested alongside the Firm. Farallon Capital Management was formed in 1986 and is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 11 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Venture M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 6 of 6 |
| Year: 2021 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-12-16 |
BioAtla
San Diego, California, United States BioAtla is a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. BioAtla was founded in 2007 and is based in San Diego, California. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-17 |
GO-JEK
Jakarta, Indonesia GO-JEK is a mobile application-based platform in Indonesia that provides a range of services such as ride-hailing, food delivery, lifestyle services, and mobile payments. GO-JEK was founded in 2010 and is based in Jakarta, Indonesia. |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 10.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
The Invus Group is a private, global investment firm that makes equity investments in private and public companies. For private companies, Invus seeks control as well as minority investments in high-growth companies where the firm can add strategic value. For public companies, Invus looks to invest in small to mid-cap stocks that are trading below the firm's assessment of their intrinsic business value. Areas of interest include consumer products and services, food, specialty retail, software, biotech, medical devices and products and services to professionals. Invus typically targets investments in the US, Europe, and Asia. The Invus Group was formed in 1985 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 9 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Venture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 8 of 8 |
| Year: 2021 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-09-13 |
Bizagi
Tysons, Virginia, United States Bizagi is an enterprise software company for digital transformation. Bizagi helps organizations to transform into digital businesses. Its process automation platform connects people, applications, devices and information to deliver the engaging experience that today’s customers demand. Bizagi was founded in 1989 and is based in Tysons, Virginia. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-27 |
AirTies
Paris, France AirTies is a provider of cloud-based managed in-home Wi-Fi solutions, serving internet service providers ("ISPs") with a combined footprint in excess of 80 million households across the world. AirTies was founded in 2004 and is based in Paris, France |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| Size | Small |
| Type | Sector Agnostic |
GV Investments is a private investment firm that invests in lower middle-market companies experiencing a change in both ownership and operating management. GV looks for companies in traditional industries such as manufacturing, wholesale/distribution and business services. Target companies are generally located in New England and have annual cash-flow of $1 to $10 million. GV will not invest in start-ups, machine/fabrication companies, software businesses, or retail. GV Investments is located in Medway, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Venture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2021 M&A | 1 of 1 |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1994 |
| PE ASSETS | 15.0B USD |
| Size | Mega |
| Type | Sector Focused |
Deerfield Management is a hedge fund sponsor focused on public and private company investments in the healthcare sector. Deerfield was established in 1994 and is headquartered in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 6 |
| Sector: Life Science M&A | 2 of 3 |
| Type: Venture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 5 of 6 |
| Year: 2021 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-05 |
Endologix
Irvine, California, United States Endologix is a medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix was founded in 1992 and is based in Irvine, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-18 |
Adaptive Phage Therapeutics
Gaithersburg, Maryland, United States Adaptive Phage Therapeutics is a U.S.-based privately-held, clinical-stage biotechnology company developing phage-based therapies to combat bacterial infections. Adaptive Phage Therapeutics is based in Gaithersburg, Maryland. |
Sell | - |
